# US 2019/0316126 A1 · Raav-based compositions and methods for treating amyotrophic lateral sclerosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0316126 A1
- Document ID: US20190316126A1
- Status: Published application
- Kind: A1
- Application number: 16/403,948
- Filed: 2019-05-06
- Published: 2019-10-17
- Earliest claimed: 2014-03-18
- Assignees: University of Massachusetts
- Applicants: University of Massachusetts
- Inventors: Christian Mueller; Robert H. Brown, JR.
- Web page: https://patentgrep.com/patent/US20190316126A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 15/86: Viral vectors
- C12Y 115/01001: Superoxide dismutase (1.15.1.1)
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N 2330/51: Specially adapted vectors
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

The invention relates to inhibitory nucleic acids and rAAV-based compositions, methods and kits useful for treating Amyotrophic Lateral Sclerosis.

## Claims

### Claim at position 1

1-50. (canceled)

### Claim 51

A synthetic miRNA that targets a C9orf72 RNA transcript, wherein the synthetic miRNA specifically binds to a nucleic acid sequence of the RNA transcript encoded by a nucleic acid sequence set forth in SEQ ID NO: 2, 6, or 7.

### Claim 52 (depends on 51)

The synthetic miRNA of claim 51, further comprising flanking regions of miR-155.

### Claim 53 (depends on 51)

The synthetic miRNA of claim 51, wherein the RNA transcript is a pre-mRNA transcript.

### Claim 54 (depends on 51)

The synthetic miRNA of claim 51, wherein the RNA transcript comprises a G4C2 hexanucleotide repeat.

### Claim 55 (depends on 53)

The synthetic miRNA of claim 53, wherein the pre-mRNA transcript is a C9orf72 V1 isoform transcript.

### Claim 56 (depends on 53)

The synthetic miRNA of claim 53, wherein the pre-mRNA transcript is a C9orf72 V3 isoform transcript.

### Claim 57 (depends on 53)

The synthetic miRNA of claim 53, wherein the pre-mRNA transcript is not a C9orf72 V2 isoform transcript.

### Claim 58 (depends on 51)

The synthetic miRNA of claim 51, wherein the RNA transcript comprises an intron.

### Claim 59

A recombinant nucleic acid encoding a synthetic miRNA that targets a C9orf72 RNA transcript, wherein the synthetic miRNA specifically binds to a nucleic acid sequence of the RNA transcript encoded by a nucleic acid sequence set forth in SEQ ID NO: 2, 6, or 7, flanked by AAV inverted terminal repeats (ITRs).

### Claim 60 (depends on 59)

The recombinant nucleic acid of claim 59, further comprising a promoter operably linked with a region encoding the synthetic miRNA.

### Claim 61 (depends on 60)

The recombinant nucleic acid of claim 60, wherein the promoter is a tissue-specific promoter.

### Claim 62 (depends on 60)

The recombinant nucleic acid of claim 60, wherein the promoter is an RNA polymerase II promoter, optionally wherein the polymerase II promoter is a chicken (3-actin (CBA) promoter.

### Claim 63 (depends on 60)

The recombinant nucleic acid of claim 60, wherein the promoter is an RNA polymerase III promoter, optionally wherein the polymerase III promoter is a U6 promoter.

### Claim 64

A recombinant adeno-associated virus (rAAV) comprising a recombinant nucleic acid encoding a synthetic miRNA that targets a C9orf72 RNA transcript, wherein the synthetic miRNA specifically binds to a nucleic acid sequence of the RNA transcript encoded by a nucleic acid sequence set forth in SEQ ID NO: 2, 6, or 7, and further comprising AAV inverted terminal repeats (ITRs).

### Claim 65 (depends on 64)

The rAAV of claim 64, further comprising one or more capsid proteins of one or more AAV serotypes selected from the group consisting of: AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV.Rh10, AAV11 and variants thereof.

### Claim 66 (depends on 64)

The rAAV of claim 64, wherein the synthetic miRNA comprises flanking regions of miR-155.

### Claim 67 (depends on 64)

The rAAV of claim 64, wherein the RNA transcript is a pre-mRNA transcript.

### Claim 68 (depends on 64)

The rAAV of claim 64, wherein the RNA transcript comprises a G4C2 hexanucleotide repeat.

### Claim 69 (depends on 64)

The rAAV of claim 64, wherein the RNA transcript comprises an intron.

### Claim 70 (depends on 64)

A composition comprising the rAAV of claim 64.
